AKT1 and neoplasm: We demonstrate that combination of zotatifin with PI3K or AKT inhibitors, which aim at vertical inhibition of the PI3K/AKT/eIF4F pathway, induce synergistic anti-tumor activity across many of these FGFR1/2 and HER2 driven tumors.